ADG116
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ADG116, covering 2026-01-08 to 2026-01-08. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients [Phase 1]